The U.S. Food and Drug Administration (FDA) has given the green light to a new combination therapy for adults suffering from specific types of relapsed or hard-to-treat large B-cell lymphomas (LBCL) who are not suitable candidates for stem cell transplants or CAR-T therapy. This innovative treatment consists of brentuximab vedotin (Adcetris), lenalidomide, and rituximab (BV+R2). It specifically targets types of LBCL such as diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL that arises from slower-growing lymphoma.
The U.S. Food and Drug Administration (FDA) has approved a new treatment regimen that includes Pfizer’s ADCETRIS® (brentuximab vedotin) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This is an important development as it provides a new option for individuals who have not responded to at least two previous therapies and are not candidates for more aggressive treatments such as stem cell transplantation or CAR T-cell therapy.
The US FDA has approved a new expanded label for Astellas Pharma’s IZERVAY™ (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) due to age-related macular degeneration (AMD) long-term. The expansion provides physicians and patients with more options for treating this progressive and chronic eye disease, which can cause irreversible vision loss.
A new study, reported at the International Stroke Conference, indicates that a medication called liraglutide, which is often used for diabetes under the brand names Victoza and Saxenda, can benefit patients who’ve had mini-strokes or transient ischemic attacks (TIAs) and have diabetes.
The study, titled “The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration,” investigates the impact of SGLT2 inhibitors on heart function in type 2 diabetes patients.
